Domestic Production Has Moved from Aspiration to Program
The legislative basis is not new. The American Medical Isotopes Production Act of 2012 established a technology-neutral program to support domestic molybdenum-99 production without highly enriched uranium, with the NNSA using cost-shared agreements and national laboratory funding to support commercial producers. The federal role has since shifted from policy design toward direct project financing. In April 2026, DOE issued SHINE Technologies a conditional loan commitment of up to $263 million to complete its Chrysalis facility in Janesville, Wisconsin, which is expected to supply more than three-quarters of US molybdenum-99 demand once operational.
Therapeutic isotopes depend on a different supply infrastructure. The Department of Energy Isotope Program supplies actinium-225, lutetium-177, lead-212, astatine-211, thorium-227, and radium-223 for cancer therapy and research, while coordinating accelerator-based actinium-225 production across Brookhaven, Los Alamos, and Oak Ridge National Laboratories. The key challenge begins upstream, where limited feedstock can constrain the entire supply chain. The International Atomic Energy Agency has established a database connecting countries holding disused radium-226 sources with partners able to convert that material into actinium-225, and Nuclear Newswire, published by the American Nuclear Society, reported in May 2026 on a collaboration between the Department of Energy, Pacific Northwest National Laboratory, and the Department of Commerce to recover radium-226 for that purpose.
New irradiation capacity is as follows. The Department of Energy Isotope Program and the University of Missouri have committed matched funding alongside the state of Missouri to establish a Radioisotope Science Center. In August 2026, a privately sited reactor built to produce medical radioisotopes rather than electricity reached criticality under the Department of Energy reactor pilot program, the first facility of its kind in the United States. Each route reactor, accelerator, or cyclotron comes with its own cost structure, regulatory requirements, and lead times, yet few developers have assessed all three against their planned launch timelines.
Capital Is Now Chasing Atoms as Hard as Molecules
Private investment has moved on an industrial scale rather than a research scale. World Nuclear News reported that construction began in Philadelphia in May 2026 on what its developer describes as the world’s largest actinium-225 manufacturing facility, a current good manufacturing practice site which, combined with expanded capacity at the operator’s existing West Coast laboratory, is intended to deliver a step change in global actinium-225 output, not an incremental one. A second dedicated actinium-225 production facility broke ground in Lansing, Michigan, in the same month. Both are multi-year builds with production expected toward the end of the decade, which is the single most important planning fact for anyone sequencing an alpha program or underwriting one.
Lutetium-177 illustrates why these lead times cannot be compressed. Producing it requires isotopically enriched targets, high-flux neutron sources, and long irradiation cycles, and the specialist workforce that manages those supply chains remains thin. For developers, contract manufacturers, nuclear pharmacies, treatment sites, and the investors funding them, the practical question is whether a supply agreement signed today will be serviced by capacity that exists today or by capacity still under construction. Radiopharmaceuticals USA 2027 examines the practical considerations shaping isotope supply, from reactor, accelerator, and cyclotron routes to domestic molybdenum-99 and actinium-225 capacity, radium-226 feedstock recovery, and the contracting models required to support radioligand therapy programs through launch.
